1 2	State of Arkansas 95th General Assembly	As Engrossed: H3/31/25 $f A~Bill$		
3	Regular Session, 2025		HOUSE BILL 1332	
4				
5	By: Representative Pilkington			
6				
7				
8	For An Act To Be Entitled			
9	AN ACT TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO			
10	COVER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, ALSO			
11	KNOWN AS GLP-1 AGONISTS, WHEN PRESCRIBED FOR WEIGHT			
12	LOSS; AND	FOR OTHER PURPOSES.		
13				
14				
15		Subtitle		
16		REQUIRE THE ARKANSAS MEDICAID PROGRAM	1	
17		COVER GLUCAGON-LIKE PEPTIDE-1		
18		EPTOR AGONISTS, ALSO KNOWN AS GLP-1		
19		VISTS, WHEN PRESCRIBED FOR WEIGHT		
20	LOSS	·		
21	DE IM DNAOMED DV MID	CONTRAL ACCOMPLY OF MAIN OF ARK	ZANGA G	
22 23	BE IT ENACTED BY THE	GENERAL ASSEMBLY OF THE STATE OF ARK	ANSAS:	
24	SECTION 1. Ark	ansas Code Title 20, Chapter 77, Sub	chapter l, is	
25	amended to add an additional section to read as follows:			
26	20-77-154. Glucagon-like peptide receptor agonists for weight loss.			
27	(a) No later than the date of issuance of a final federal rule			
28	resulting from the proposed federal rule published as Medicare and Medicaid			
29	Programs: Contract Year 2026 Policy and Technical Changes to the Medicare			
30	Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost			
31	Plan Program, and Programs of All-Inclusive Care for the Elderly, 89 Fed.			
32	Reg. 90.340 (December 10, 2024), the Arkansas Medicaid Program shall cover			
33	glucagon-like peptide-l receptor agonists, also known as GLP-l agonists, when			
34	prescribed for weight loss.			
35	_	ment of Human Services shall apply f		
36	waiver, state plan am	endment, or other authorization nece	ssary to implement	

1	this section.	
2		
3		
4		/s/Pilkington
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
<ul><li>26</li><li>27</li></ul>		
28		
29		
30		
31		
32		
33		
34		
35		
36		